Second-Quarter 2020 Business Performance Preannouncement
bioMerieux CE Mark of VIDAS Serology test for SARS-COV-2
bioMérieux announces the CE marking of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to SARS-CoV-2 which causes the COVID-19 disease. Read more here
COVID-19 Business Continuity
Information on business continuity for all our customers at the current time.
Introducing a total sepsis solution at NHS Greater Glasgow and Clyde
A campaign to raise awareness of sepsis in Scotland, combined with the introduction of the latest technology in microbiology, has had a positive impact on the speed of clinical intervention and potential outcomes in the fight against this serious condition, as Janet Young explains. Read the full article here. (Licenced from Pathology in Practice Volume 20, Issue 5, October 2019)
bioMerieux Webinar on Endotoxin Testing
Are you interested in understanding the use, applications and approval process of sustainable rFC tests for endotoxin?